Bionano Genomics, Inc.
About Bionano Genomics, Inc.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $28.5M
- Net income
- -$26.4M
- Total assets
- $73.6M
- Market cap
- $13.4M
- Gross margin
- 46.3%
- Operating margin
- -116.9%
- Net margin
- -92.6%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $28.5M
- Cost of revenue
- $15.3M
- Gross profit
- $13.2M
- Operating expenses
- $46.5M
- Operating income
- -$33.3M
- Income tax
- $67.0K
- Net income
- -$26.4M
- EPS (basic)
- $-4.85
- EPS (diluted)
- $-4.85
Balance sheet
- Total assets
- $73.6M
- Current assets
- $45.4M
- Total liabilities
- $29.2M
- Current liabilities
- $22.9M
- Shareholders’ equity
- $44.4M
Cash flow
- Operating cash flow
- -$16.3M
- Investing cash flow
- -$12.7M
- Financing cash flow
- $24.0M
- Net cash flow
- -$5.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $13.4M
- EPS (diluted)
- $-4.85
- Shares outstanding
- 11.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 1, 2018
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $26.4M in FY2025.
- Revenue grew 59% from FY2021 to FY2025.
- Gross margin of 46.3%, net margin -92.6%.
- Trading 76% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Bionano Genomics, Inc..
Write a review
News about Bionano Genomics, Inc.
News & sentiment via Polygon.io
